Enrolling Patients for PROVENGE Immunotherapy

Patient enrollment begins with patient and provider consent, and also includes verifying benefits and determining eligibility for patient assistance. Once a patient is enrolled, you can securely track your patient’s treatment progress online.

Get Started With Dendreon ON Call

Personal and Comprehensive Support for Practices

Dendreon ON Call provides dedicated case managers to support your patients and practice throughout patient enrollment, benefits verification, and the scheduling process.
  • Enroll patients online or contact Dendreon ON Call by phone to get started
  • Enroll and securely track your patient’s treatment progress through the Dendreon ON Call secure Provider Portal
  • Utilize eSign, a feature that enables patients to electronically sign their enrollment form either (1) in the physician’s office via our secure provider portal, or (2) remotely, via email, if the patient did not provide a wet signature in the office. eSign enhances convenience, streamlines enrollment for you, your patients and your practice.

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.

Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.

Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or

PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Click here for Prescribing Information.